STOCK TITAN

22nd Century Group to Announce Third Quarter 2026 Results on November 16, 2026

22nd Century Group (XXII) will report its third-quarter 2026 results on November 16, 2026, followed by a webcast that morning.

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date

22nd Century Group (XXII) will report its third-quarter 2026 results on November 16, 2026, followed by a webcast that morning. The results release is scheduled for approximately 6:00 AM ET, with the webcast at 8:00 AM ET. Chairman and CEO Larry Firestone and CFO Dan Otto will review financial results and provide updates on commercial, regulatory and operational activities. A live and archived webcast will be available through the company's investor relations Events page.

Loading...
Loading translation...
Argus 15 min delay 101 alerts
-2.28% vs previous close $0.0472 last price 17.0x rel. volume Open Argus
Details

Market Reaction – XXII

+3.2% Peak in 0 min
$0.04 – $0.07 Day Range
$906,344 Mkt Cap at Last Price

On Nov 3, the day this news came out, the latest delayed price for XXII is 2.28% below the previous close. Argus tracked a peak move of +3.2% during the session. Our momentum scanner has recorded 101 alerts for this stock so far that day. The latest delayed price is $0.05. Relative volume is exceptionally heavy at 17.0x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Results announcement: November 16, 2026, approximately 6:00 AM ET
Results announcement
November 16, 2026, approximately 6:00 AM ET
Third-quarter 2026 results press release

Key Terms

alkaloid biosynthesis
1 terms
alkaloid biosynthesis technical
"technologies that regulate alkaloid biosynthesis activities"
Alkaloid biosynthesis is the set of natural chemical steps inside plants, fungi or microbes that build alkaloids — a class of nitrogen-containing molecules that include many medicines, stimulants and defensive toxins. For investors, controlling or scaling these pathways is like improving a factory assembly line: it affects how much of a valuable compound can be produced, the cost and consistency of supply, intellectual property and regulatory or safety risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MOCKSVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only low nicotine tobacco company in the world, will host a webcast on Monday, November 16, 2026, at 8:00 AM ET to discuss its 2026 third quarter results, which are to be reported in a press release at approximately 6:00 AM ET the same day.

During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results and provide an update on recent commercial, regulatory and operational activities.

The live and archived webcast will be accessible on the Events web page in the Company's Investor Relations section of the website, at https://ir.xxiicentury.com/events. Please access the website at least 10 minutes prior to the start of the webcast to register and, if necessary, download and install any required software.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship low nicotine cigarette products , the VLN® cigarette and Pinnacle VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. Our VLN® cigarettes are the lowest nicotine cigarettes in America™ and have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

FDA Authorized

Our VLN® cigarettes are the only low nicotine combustible cigarette authorized by the FDA in the United States.

VLN® is a registered trademark of 22nd Century Limited LLC.

Learn more about 22nd Century at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN® cigarettes at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Report on Form 10-Q filed on May 7, 2026 and August 13, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Daniel Otto
Chief Financial Officer & Investor Relations
22nd Century Group
investorrelations@xxiicentury.com


Keep reading